Are Analysts Bearish MacroGenics, Inc. (NASDAQ:MGNX) After Last Week?

April 25, 2018 - By Henry Gaston

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.47, from 1.58 in 2017Q3. It dived, as 14 investors sold MacroGenics, Inc. shares while 31 reduced holdings. 15 funds opened positions while 35 raised stakes. 28.26 million shares or 1.97% more from 27.72 million shares in 2017Q3 were reported.
Rhenman Prtn Asset Mngmt reported 308,604 shares. Private Advsr invested 0.12% in MacroGenics, Inc. (NASDAQ:MGNX). 35,742 are owned by Credit Suisse Ag. Vident Advisory Limited Liability Corporation stated it has 65,643 shares. Gam Hldgs Ag reported 22,600 shares. Fmr Lc invested in 0.01% or 3.64M shares. Schwab Charles Inv Incorporated invested in 175,106 shares. 632,521 are owned by Hood River Cap Mgmt Ltd Liability Corporation. Barclays Public Limited Company accumulated 8,282 shares. Invesco Ltd holds 16,371 shares or 0% of its portfolio. Art Advisors Ltd Liability accumulated 34,493 shares or 0.03% of the stock. Bnp Paribas Arbitrage has 7,020 shares for 0% of their portfolio. Alliancebernstein Limited Partnership has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 43,000 shares. Us National Bank & Trust De has 572 shares for 0% of their portfolio. Deutsche Comml Bank Ag holds 221,852 shares or 0% of its portfolio.

Since October 25, 2017, it had 0 buys, and 7 insider sales for $1.10 million activity. Cilinski Lynn also sold $599,436 worth of MacroGenics, Inc. (NASDAQ:MGNX) on Wednesday, February 28. On Monday, March 5 Karrels James sold $155,000 worth of MacroGenics, Inc. (NASDAQ:MGNX) or 5,000 shares. The insider Wigginton Jon Marc sold 5,000 shares worth $100,000.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 7 analysts covering Macrogenics (NASDAQ:MGNX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Macrogenics had 7 analyst reports since November 10, 2017 according to SRatingsIntel. The stock of MacroGenics, Inc. (NASDAQ:MGNX) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, March 14. Citigroup maintained the shares of MGNX in report on Friday, November 10 with “Neutral” rating. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Buy” rating given on Friday, January 19 by BTIG Research. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Buy” rating given on Friday, April 6 by Leerink Swann. SunTrust maintained the stock with “Buy” rating in Tuesday, January 23 report. Below is a list of MacroGenics, Inc. (NASDAQ:MGNX) latest ratings and price target changes.

06/04/2018 Broker: Leerink Swann Rating: Buy New Target: $35.0000 Initiate
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 New Target: $26 Maintain
05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38 Initiates Coverage On
23/01/2018 Broker: SunTrust Rating: Buy New Target: $31.0 Maintain
19/01/2018 Broker: BTIG Research Rating: Buy New Target: $28.0 Maintain
11/12/2017 Broker: Raymond James Rating: Buy
10/11/2017 Broker: Citigroup Rating: Neutral Old Target: $18 New Target: $22 Maintain

The stock decreased 1.13% or $0.26 during the last trading session, reaching $22.72. About 4,450 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 31.18% since April 25, 2017 and is uptrending. It has outperformed by 19.63% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $958.74 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: